Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize
by Zacks Equity Research
Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.
Top Stock Analyst Reports for Merck, Philip Morris & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Philip Morris International (PM) and American Tower (AMT).
Company News for Feb 11, 2020
by Zacks Equity Research
Companies in the news are: QSR, CNA, MPAA, AGN
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
What's in Store for Ironwood (IRWD) This Earnings Season?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up
by Zacks Equity Research
AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Can Humira/Cancer Drugs Help AbbVie (ABBV) Beat Q4 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs are likely to have witnessed strong growth.
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review
by Zacks Equity Research
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.
Allergan (AGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
by Zacks Equity Research
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
Is Allergan (AGN) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.
J&J Seeks Label Expansion for Spravato Nasal Spray in EU
by Zacks Equity Research
J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
by Benjamin Rains
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
by Zacks Equity Research
Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
Amgen Stock Up in a Year on Pipeline & Biosimilar Progress
by Zacks Equity Research
Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.
3 Stocks with Solid Entry Points to Consider for 2020
by Christopher Vargas
Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump's airstrike killed Iran's top military commander.
Aerie's (AERI) Application for Roclanda Accepted in Europe
by Zacks Equity Research
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
by Zacks Equity Research
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.